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Summary
Background and purpose: Previous studies suggested that statins have pleiotropic
effects, such as improvements in endothelial function, as well as anti-inﬂammatory,
anti-proliferative, and anti-oxidative effects. These effects might beneﬁt patients
with heart failure. In those patients, statins relieved symptoms, decreased the
frequency of hospitalization, suppressed neurohumoral activation, and improved
cardiac function. However, it remains unknown how statins impact pathophysiology
of heart failure with diabetes mellitus. The aim of this study was to investigate
the effects of atorvastatin on pathophysiology of heart failure with diabetes melli-
tus.
Methods and results:We enrolled retrospectively 128 patients with heart failure with
diabetes mellitus who were admitted from January 2003 to December 2005. Among
these patients, 80 received atorvastatin (statin group) and the remaining patients
served as controls (non-statin group). At study entry, there were no signiﬁcant dif-
ferences in the patient proﬁles between the two groups except for the low-density
lipoprotein cholesterol level being higher in the statin group. After the follow-up
period of two years, the frequency of re-hospitalization, brain natriuretic peptide,
premature ventricular contractions, Lown grade, and deterioration of glomerular
ﬁltration rate were signiﬁcantly less in the statin group.
∗ Corresponding author. Tel.: +81 92 642 5360; fax: +81 92 642 5374.
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Conclusion: Atorvastatin might beneﬁt patients with heart failure and diabetes mel-
litus by improving ventricular electrical stability and decelerating deterioration of
renal function.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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re-hospitalization due to worsening heart failure
between the statin and non-statin groups was com-© 2009 Japanese Colleg
reserved.
Introduction
Previous randomized clinical trials have shown that
statins reduce cardiovascular events in patients
with and/or without coronary artery disease.
Statins have been shown to improve endothelial
function [1], decrease plasma levels of proinﬂam-
matory cytokines [2], and exert antihypertrophic
[3,4], antioxidant [5], and antiﬁbrotic [6] effects on
myocardium. Furthermore, other reports suggested
that statins have beneﬁcial effects on immune
function, macrophage metabolism, and cell pro-
liferation irrespective of changes in low-density
lipoprotein (LDL) cholesterol concentrations [7].
Recent clinical trials suggested that statins
might beneﬁt patients with heart failure [8—13].
Short-term statin therapy improved cardiac func-
tion, neurohumoral imbalance, and symptoms in
patients with idiopathic dilated cardiomyopathy
[8]. Long-term atorvastatin therapy suppressed
neurohumoral activation and improved cardiac
function in mild to moderate heart failure [9]. Com-
pared with a lower dose, high-dose treatment with
atorvastatin in patients with stable coronary dis-
ease signiﬁcantly reduced hospitalization for heart
failure [10]. However, it remains unknown how
statins impact pathophysiology of heart failure with
diabetes mellitus, which is known to have delete-
rious effects on heart failure [14,15] and coronary
artery disease [16].
The aim of this study was to investigate the
effects of atorvastatin on pathophysiology of heart
failure with diabetes mellitus. The results indicated
that atorvastatin might beneﬁt heart failure with
diabetes mellitus by improving ventricular elec-
trostability and decelerating the deterioration of
renal function.
Subjects and methods
Patient populations
We retrospectively studied patients with symp-
tomatic acute heart failure and diabetes mellitus
who were admitted to Aso Iizuka Hospital from
January 2003 to December 2005. The criteria for
enrollment in the study were the clinical evidence
of acute heart failure diagnosed by Framingham
p
w
t
vriteria [17], and diabetes mellitus diagnosed by
he guideline of diabetes mellitus of the Japan
iabetes Society. In those patients, the New York
eart Association (NYHA) functional classiﬁcation
n admission ranged between II and IV. We excluded
hronic obstructive pulmonary disease, right heart
ailure, and patients who had already taken ator-
astatin or other statins. All patients were treated
or acute heart failure, and were discharged after
he improvement of heart failure. We enrolled 128
atients with heart failure and diabetes mellitus.
mong them, 80 patients started to receive ator-
astatin (10mg) and the remaining 48 patients did
ot receive any statins (non-statin group). We fol-
owed up both groups for two years. As biochemical
iomarkers, we measured plasma brain natriuretic
eptide (BNP) and hemoglobin A1c (HbA1c). We
alculated estimate of glomerular ﬁltration rate
eGFR) from serum creatinine value and age using
apanese-coefﬁcient-modiﬁed MDRD study [18]. As
hysiological biomarkers, we conducted echocar-
iography and 24-h Holter monitoring, and the
everity of ventricular arrhythmias was evaluated
n terms of Lown grade [grade 0: no premature
entricular contraction (PVC); grade I: <30 PVC/h,
rade II: >30 PVC/h; grade III: multiform PVC;
rade IVa: couplets; grade IVb; ventricular tachy-
ardia runs] [19]. We acquired those biomarkers
ust before the statin therapy in the statin group
nd before discharge in the non-statin group, and
ne and two years after the discharge in both
roup. Hospitalizations due to worsening heart fail-
re were diagnosed by the Framingham criteria, as
escribed above.
tatistical analysis
ormally distributed variables were expressed as
ean± S.D. Unpaired t test or Mann—Whitney U
est was used to compare the differences in nor-
ally distributed variables, respectively, between
he statin and non-statin groups. The rate ofared by Kaplan—Meier analysis. All statistical tests
ere carried out against the baseline characteris-
ics. Differences were considered signiﬁcant at a p
alue of <0.05.
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Table 1 Patient characteristics.
Statin Non-statin P-value
n 80 48 NS
Male/female 54/26 34/14 NS
Age 65± 7 61± 5 NS
BMI 22± 4 23± 3 NS
Current smoker 18 (23%) 10 (20%) <0.05
Causes of heart failure
Coronary artery disease 22 (27%) 9 (18%) NS
Dilated cardiomyopathy 25 (32%) 13 (28%) NS
Hypertensive heart disease 14 (18%) 10 (21%) NS
Valvular heart disease 15 (19%) 11 (23%) NS
Systolic blood pressure (mmHg) 130± 17 128± 14 NS
Diastolic blood pressure (mmHg) 72± 14 68± 9 NS
Heart rate (bpm) 82± 9 79± 5 NS
Medications
Diuretics 74 (92%) 44 (92%) NS
-Blockers 53 (66%) 34 (71%) NS
ACE inhibitors 75 (94%) 46 (96%) NS
Angiotensin receptor blocker 3 (4%) 2 (4%) NS
Sulfonylurea 12 (15%) 8 (17%) NS
mass
R
P
T
i
t
dData are presented as number (%) or mean± S.D. BMI, body
enzyme.
esultsatient characteristics at baseline
he patient proﬁles at enrollment are summarized
n Tables 1 and 2. As can be seen in Table 1,
h
e
j
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Table 2 Patient characteristics (2).
Statin
Total cholesterol (mg/dl) 227± 17
LDL cholesterol (mg/dl) 156± 11
HDL cholesterol (mg/dl) 44± 8
Triglycerides (mg/dl) 129± 7
FBS (mg/dl) 112± 7
HbA1c (%) 6.6± 0.7
BNP (pg/ml) 128± 27
eGFR (ml/min/1.73m2) 62.4± 7.9
LVEF (%) 35± 7
LVEDD (mm) 56± 5
LVESD (mm) 40± 4
PVC per 24 h 1288± 362
Lown grade
I 28 (35%)
II 43 (54%)
III 8 (10%)
IVa/IVb 1 (1%)/0 (0%)
Data are presented as mean± S.D. LDL, low-density lipoprotein; HD
hemoglobin A1c; BNP, brain natriuretic peptide; eGFR, creatinine-ba
ejection fraction; LVDDD, left ventricular end-diastolic dimension; L
ventricular contraction.index; bpm, beats per minute; ACE, angiotensin-converting
here were no signiﬁcant differences in age, gen-
er, or the prevalence of dilated cardiomyopathy,
ypertensive heart disease, or valvular heart dis-
ase between the non-statin group and statin group
ust before statin therapy. Medications did not
iffer either. The frequency of patients taking
Non-statin P-value
200± 10 0.042
122± 13 0.008
47± 7 NS
132± 11 NS
119± 5 NS
6.3± 0.4 NS
142± 36 NS
66.8± 4.4 NS
33± 5 NS
57± 7 NS
42± 7 NS
1194± 443 NS
15 (31%) NS
26 (54%) NS
6 (13%) NS
1 (2%)/0 (0%) NS/NS
L, high-density lipoprotein; FBS, fasting blood glucose; HbA1c,
sed estimate of glomerular ﬁltration rate; LVEF, left ventricular
VESD, left ventricular end-systolic dimension; PVC, premature
T. Kishi et al.
Figure 1 Changes in eGFR at entry, one and two
years. Open circle and solid line indicate statin group.
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angiotensin receptor blockers or oral hypoglycemic
agents also did not differ between the non-statin
and statin groups. All patients with hypoglycemic
agents took sulfonylurea. There is no patient with
insulin-therapy for diabetes mellitus in the present
study. As anticipated, the statin group had a higher
prevalence of coronary artery disease than the non-
statin group.
As shown in Table 2, fasting blood glucose (FBG),
HbA1c, BNP, or eGFR did not differ between the two
groups. As anticipated, however, total cholesterol
and LDL cholesterol were higher in the statin group
than in the non-statin group. Left ventricular ejec-
tion fraction (LVEF), left ventricular end-diastolic
dimension (LVEDD), left ventricular end-systolic
dimension (LVESD), the frequency of PVC and the
frequency of patients who had Lown grade I, II, III,
or IV did not differ between the two groups. There
is no patient with Lown grade 0 in the present study.
Effects of atorvastatin on biochemical and
physiological biomarkers
Effects of atorvastatin on biochemical biomarkers
are summarized in Table 3. Atorvastatin markedly
decreased total cholesterol and LDL cholesterol.
As a result, LDL cholesterol values at the follow-
up period of one year were comparable between
r
n
2
Table 3 Changes in LDL-C, BNP, LVEF, LV dimension, systoli
Statin
LDL-C (mg/dl)
1 year 98± 16
2 years 94± 9
BNP (pg/ml)
1 year 101± 12
2 years 76± 11
LVEF (%)
1 year 38± 6
2 years 40± 7
LVEDD/LVESD (mm)
1 year 57± 6/41± 4
2 years 58± 4/42± 4
Systolic blood pressure (mmHg)
1 year 118± 13
2 years 116± 11
HbA1c (%)
1 year 6.4± 0.3
2 years 6.1± 0.4
Data are presented as mean± S.D. LDL-C, low-density lipoprotein c
ular ejection fraction; LVEDD, left ventricular end-diastolic dimen
hemoglobin A1c.losed circle and dotted line indicate non-statin group.
p < 0.05. eGFR, creatinine-based estimate of glomerular
ltration rate.
he two groups and got lower at two years in the
tatin group than the non-statin group. BNP was
ower at one year and got lower at two years in
he statin group than the non-statin group. Sys-
olic blood pressure, LVEF, LVEDD, LVESD, and HbA1c
emained not different between the two groups.
As shown in Fig. 1, eGFR decreased more in the
on-statin group than in the statin-group (−10.6±
.8ml/min/1.73m2 vs. −6.1± 3.3ml/min/1.73
c blood pressure, and HbA1c at one and two years.
Non-statin P-value
116± 13 NS
112± 11 <0.05
136± 13 <0.05
132± 13 <0.05
35± 6 NS
38± 7 NS
59± 4/44± 5 NS/NS
60± 7/46± 7 NS/NS
122± 15 NS
120± 13 NS
6.5± 0.4 NS
6.5± 0.3 NS
holesterol; BNP, brain natriuretic peptide; LVEF, left ventric-
sion; LVESD, left ventricular end-systolic dimension; HbA1c,
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Figure 2 Changes in PVCs at entry, one, and two years.
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Table 4 Cardiovascular events, hospitalization, and
mortality at one and two years.
Statin Non-statin P-value
Cardiovascular events
1 year 5 (6%) 4 (8%) NS
2 years 8 (10%) 6 (13%) NS
CHF with hospitalization
1 year 7 (9%) 8 (17%) 0.003
2 years 16 (20%) 15 (31%) 0.005
All-cause mortality
1 year 0 0 NS
2 years 0 1 NS
C
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F
gpen circle and solid line indicate statin group. Closed
ircle and dotted line indicate non-statin group. *p < 0.05.
VC, premature ventricular contraction.
2, p < 0.05) at one year. The difference increased
t two years (−16.8± 4.1ml/min/1.73m2 vs.
8.3± 5.4ml/min/1.73m2, p < 0.05). Atorvas-
atin might have decelerated deterioration of
enal function, and thereby might have a potent
rotective effect on renal function.
Shown in Fig. 2 is the effect of atorvastatin
n the frequency of PVCs. Atorvastatin markedly
ecreased PVCs at one year and two years. There
ere no changes in PVCs in the non-statin group.
urthermore, the frequency of patients who had
own grade ≥II was signiﬁcantly lower in the statin
roup than in the non-statin group at one year and
wo years (Fig. 3).
t
e
(
igure 3 Kaplan—Meier analysis estimates for re-hospitaliza
roup, and dotted line indicates statin-group. *p < 0.05.Data are presented as number (%) or mean± S.D. CHF, con-
gestive heart failure.
ardiovascular events and hospitalization
o patient died in the statin group, whereas one
atient suddenly died in the non-statin group.
reatment with atorvastatin did not signiﬁcantly
educe cardiovascular events, which was deﬁned as
onfatal myocardial infarction, nonfatal ischemic
troke, coronary revascularization, or cardiovas-
ular death (Table 4). However, the frequency of
e-hospitalization due to worsening heart failure
as signiﬁcantly reduced in the statin group than in
he non-statin group, determined by Kaplan—Meier
nalysis (Fig. 4). For the patients with atorvastatin,
he hazard ratio for re-hospitalization due to wors-
ning heart failure was 0.68 (95% CI, 0.51—0.84)
Fig. 4).
tion due to heart failure. Solid line indicates non-statin
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PVC/h; grade III: multiform PVC; grade IV: couplets and/
Discussion
In the present study, we demonstrated that
atorvastatin reduced the frequency of re-
hospitalization due to worsening heart failure,
BNP, the frequency of PVCs, Lown grade and
decelerated deterioration of GFR in the patients
with heart failure and diabetes mellitus. These
results suggested that atorvastatin might ben-
eﬁt patients with heart failure and diabetes
mellitus by improving ventricular electrostability
and decelerating deterioration of renal function.
Recent clinical trials and basic studies suggested
that statins might beneﬁt patients with heart
failure [8—13,20—24]. In the present study, atorvas-
tatin reduced the frequency of re-hospitalization
due to worsening heart failure and BNP. These
results are comparable to previous studies, which
showed that statins might beneﬁt patients with
heart failure. Furthermore, the present study sug-
gested that atorvastatin has beneﬁcial effects on
the pathophysiology of heart failure with diabetes
mellitus, which is known to have deleterious effects
on heart failure [14,15]. In the statin group, the LDL
cholesterol level was signiﬁcantly higher than in the
non-statin group at entry. Atorvastatin markedly
decreased the LDL cholesterol level, and the LDL
cholesterol levels at the follow-up period of one
year were comparable between the two groups. The
LDL cholesterol levels were signiﬁcantly lower at
two years in the statin group than the non-statin
group. The statin group had a higher prevalence
of coronary atherosclerotic diseases than the non-
statin group. These differences of backgrounds
between the statin and non-statin groups might be
responsible for the results in this study. However,
these results indicate that the risks for atheroscle-
t
a
w
aer (grade 0: no PVC; grade I: <30 PVC/h, grade II: >30
ntricular tachycardia runs). *p < 0.05.
osis and ischemic heart diseases were higher in
he statin group than in the non-statin group.
espite those with a background predisposed to
oronary heart disease, atorvastatin signiﬁcantly
eneﬁts the patients with heart failure. It is con-
eivable that atorvastatin might be a novel strategy
f treatment for heart failure and diabetes melli-
us.
The mechanism by which atorvastatin ben-
ﬁts patients with heart failure and diabetes
ellitus remains unknown. We conjecture three
echanisms: anti-oxidant, anti-inﬂammatory, and
mprovement of the sympatho-vagal balance. In
atients with heart failure, increased oxidative
tress is associated with reduced LV function
nd severity of heart failure [25,26]. Previous
tudies suggested that statins inhibited vascu-
ar and myocardial oxidative stress by inhibiting
ac-induced nicotinamide adenine dinucleotide
hosphatase oxidase activity [27,28], and reducing
xidized LDL concentration [9], which is a marker
f oxidative stress and a useful predictor of mortal-
ty in patients with heart failure [29]. Furthermore,
iabetes mellitus increases the risk of heart failure
nd oxidative stress may contribute to the devel-
pment of cardiac dysfunction [30]. With regard
o the anti-inﬂammatory effects of atorvastatin,
revious studies reported that statins suppressed
he inﬂammatory process in patients with heart
ailure [8,21,22]. Heart failure is associated with
ncreased levels of proinﬂammatory cytokines that
xert negative inotropic effects and induce apopto-
is in cardiac myocytes [31]. Yamada et al. reported
hat atorvastatin tended to decrease interleukin 6
nd high sensitive C-reactive protein in patients
ith heart failure [9]. Finally, we consider that
torvastatin might improve the imbalance between
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[torvastatin beneﬁts heart failure patients with dia
he sympathetic and parasympathetic nerve activ-
ty and this improvement resulted in the reduction
f the frequency of PVCs. A previous study reported
hat statin therapy restored sympatho-vagal bal-
nce in experimental heart failure [23]. We have
emonstrated that atorvastatin reduced the oxida-
ive stress in the cardiovascular center of the
rainstem [32], in which oxidative stress increased
ympathetic nerve activity in hypertensive animal
odels [33]. These reports suggest that atorvas-
atin might reduce the oxidative stress in the
ardiovascular center, which, in turn, decreases the
ympathetic nerve activity, the frequency of PVCs,
nd Lown grade. Further investigations are needed
o clarify the mechanisms.
Renal dysfunction has been known to worsen
eart failure [34]. Campese and Park suggested
hat statin-mediated alterations in inﬂammatory
esponses and endothelial function reduced pro-
einuria and the rate of progression of kidney
isease [35]. In the present study, atorvastatin pro-
ected the progressive worsening in renal function
or two years in the patients with heart failure
nd diabetes mellitus. These results suggest that
torvastatin might prevent the worsening of heart
ailure through a renoprotective effect. Additional
rospective and randomized trials in the Japanese
opulation are needed to determine whether ator-
astatin is truly renoprotective.
imitations
here are several limitations to the present study.
irst, the study was retrospective, and observa-
ional. The number of patients enrolled is also
imited. Second, we were not able to determine
hether the beneﬁcial effect of atorvastatin on
eart failure with diabetes mellitus is a class
ffect or not. The results of the present study
hould be validated by large, prospective, well-
ontrolled, and randomized clinical trials. Third,
e did not measure the activity of sympathetic
erve activity, parasympathetic nerve activity, and
ympatho-vagal balance using variability of R—R
nterval and blood pressure analysis. In the present
tudy, we are not able to suggest that the data indi-
ate the improvement of the imbalance between
ympathetic and parasympathetic nerve activity by
torvastatin in heart failure with diabetes mellitus.onclusion
torvastatin might beneﬁt patients with heart fail-
re and diabetes by improving ventricular electrical
[es 347
tability and decelerating deterioration of renal
unction. Atorvastatin might be a novel strategy of
reatment for heart failure and diabetes.
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